Derma Sciences Appoints Medical Device Veteran Amy S. Paul to Its Board of Directors

  Derma Sciences Appoints Medical Device Veteran Amy S. Paul to Its Board of

Business Wire

PRINCETON, N.J. -- May 24, 2013

Derma Sciences, Inc. (Nasdaq: DSCI), a medical device and pharmaceutical
company focused on advanced wound care, announces the appointment of medical
device veteran Amy S. Paul to the Company’s board of directors, effective May
23, 2013. Ms. Paul fills the seat vacated by James T. O’Brian, who is leaving
the board following 12 years of service.

Ms. Paul retired in 2008 following a 26-year career with C.R. Bard, Inc., a
$2.8 billion global medical device company, most recently as Group Vice
President – International. Previous positions at C.R. Bard included President
of Bard Access System, Inc., President of Bard Endoscopic Technologies, Vice
President and Business Manager of Bard Ventures, Vice President of Marketing
of Bard Cardiopulmonary Division and Marketing Manager for Davol Inc.

“Amy is an accomplished and highly regarded medical device industry leader
upon whose expertise we will rely as we grow our advanced wound care business
both domestically and internationally. We are fortunate that an executive of
her caliber has chosen to join our board,” said Edward J. Quilty, chairman and
chief executive officer of Derma Sciences. “On behalf of the employees and
directors of Derma Sciences, I would like to thank Jim O’Brian for his years
of service to our company. Jim helped guide us through a transformation that
now features a focus on providing ‘go-to’ products to treat chronic wounds and
a dedicated sales force to market them.”

Ms. Paul currently serves as a director of Wright Medical Group, Inc. (Nasdaq:
WMGI), a global orthopaedic medical device company, and previously served on
the board of directors of Viking Systems, prior to its acquisition by CONMED
Corporation. She is a member of the Northwest Commission for Colleges and
Universities, an accreditation body for colleges and universities in seven
western states.

Ms. Paul holds an M.B.A. and a B.A. cum laude from Boston University.

About Derma Sciences, Inc.

Derma Sciences is a medical technology company focused on three segments of
the wound care marketplace: pharmaceutical wound care products; advanced wound
care dressings to address chronic wounds including diabetic ulcers; and
traditional dressings. The Company has begun its Phase 3 clinical trial in
diabetic foot ulcer healing with DSC127, based on excellent Phase 2 data. Its
MEDIHONEY® product is the leading brand of honey-based dressings for the
management of wounds and burns. The product has been shown to be effective in
a variety of indications and was the focus of a positive large-scale,
randomized controlled trial involving 108 subjects with leg ulcers. TCC-EZ® is
its gold-standard total contact casting system for diabetic foot ulcers. Other
novel products introduced into the $14 billion global wound care market
include XTRASORB® for better management of wound exudate, and BIOGUARD® for
infection prevention.

For more information please visit

Forward-Looking Statements

Statements contained in this news release that are not statements of
historical fact may be deemed to be forward-looking statements. Without
limiting the generality of the foregoing, words such as "may," "will,"
"expect," "believe," "anticipate," "intend," "could," "estimate" or "continue"
are intended to identify forward-looking statements. Readers are cautioned
that certain important factors may affect the Company's actual results and
could cause such results to differ materially from any forward-looking
statements that may be made in this news release or that are otherwise made by
or on behalf of the Company. Factors that may affect the Company's results
include, but are not limited to, product demand, market acceptance, impact of
competitive products and prices, product development, completion of an
acquisition, commercialization or technological difficulties, the success or
failure of negotiations and trade, legal, social and economic risks.
Additional factors that could cause or contribute to differences between the
Company's actual results and forward-looking statements include but are not
limited to, those discussed in the Company's filings with the U.S. Securities
and Exchange Commission.


Derma Sciences, Inc.
John E. Yetter, 609-514-4744
Executive Vice President of Finance, CFO
Kim Sutton Golodetz, 212-838-3777
Bruce Voss, 310-691-7100
Press spacebar to pause and continue. Press esc to stop.